Changeflow GovPing Pharma & Drug Safety Pharmaceutical Composition for Prevention or Tr...
Routine Notice Added Final

Pharmaceutical Composition for Prevention or Treatment of Post-Surgical Pain

Favicon for changeflow.com EPO Patent Bulletin - Therapeutics (A61P)
Published
Detected
Email

Summary

EPO published patent application EP4084818A2 by Peptinov covering a pharmaceutical composition for preventing or treating post-surgical pain. The composition is classified under IPC codes A61K 38/17, A61K 38/20, and A61P 29/00, with inventors including Azoulai, Cassard, Salles, and Zagury. Designated states cover 31 European countries including major markets.

What changed

The EPO published patent application EP4084818A2 for a pharmaceutical composition developed by Peptinov intended for the prevention or treatment of post-surgical pain. The composition falls under therapeutic classifications related to proteins/peptides (A61K 38/17, A61K 38/20) and analgesics (A61P 29/00). The patent designates 31 European contracting states including Germany, France, Italy, Spain, and the UK.

This publication is informational regarding intellectual property rights and does not impose compliance obligations on pharmaceutical manufacturers or healthcare providers. Companies developing competing pain management therapies should review this patent for freedom-to-operate considerations. The patent grants Peptinov exclusive rights to the claimed composition in designated European states.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF POST-SURGICAL PAIN

Publication EP4084818A2 Kind: A2 Mar 25, 2026

Applicants

Peptinov

Inventors

AZOULAI, René, CASSARD, Xavier, SALLES, Jean-Pierre, ZAGURY, Jean-François

IPC Classifications

A61K 38/17 20060101AFI20220729BHEP A61K 38/20 20060101ALI20220729BHEP A61P 29/00 20060101ALI20220729BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

A61K 38/17 - Proteins from 20-150 amino acids A61K 38/20 - Interleukins A61P 29/00 - Non-opioid analgesics and antipyretics

Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
March 25th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4084818A2

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Patients
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Patent Application Pharmaceutical Manufacturing Drug Development
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Healthcare Intellectual Property

Get alerts for this source

We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!